Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T cells.
PD-1 and its ligands, PD-L1 and PD-L2, are members of the cluster of differentiation (CD)28 and B7 family. The B7 family cell surface molecules and the cytotoxic T-lymphocyte antigen 4 family both regulate complex signaling pathways that affect T-cell activation, tolerance, and immunopathology.
Blocking the interactions between PD-1 and its corresponding ligands prevents T-cell exhaustion in patients with cancer, allowing the T cells to combat the tumor via natural immune response mechanisms.
- Opdivo: Colorectal cancer (CRC)
- Opdivo: Head and neck cancer
- Opdivo: Hepatocellular carcinoma (HCC)
- Opdivo: Bladder cancer
- Opdivo: Glioblastoma (GBM)
- Opdivo: Renal cell cancer (RCC)
- Opdivo: Non-small cell lung cancer (NSCLC)
- Opdivo: Gastric cancer
- Opdivo: Melanoma
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/sx5njt/2018_opdivo?w=4